www.genotec-frankfurt.de/bio-pharmazeutika-werden-zu-einer-anerkannten-form-der-alternativmedizin/
The focus of the industry on living human beings and highly regulated standards make it a unique challenge for business leaders. These characteristics make the industry an ideal environment for innovation. They have led to major breakthroughs in biofuels, crop yields, and life-saving pharmaceuticals.
When you think of strategies to generate revenue biotech start-ups have a myriad of options. Most choose a technology partnership or an asset creation-and-out licensing strategy. Technology partnering generates faster revenue and lower financial risk while out-licensing and asset creation strategy can yield significantly greater returns if it’s successful. An increasing number of biotechs in the research stage operate in a hybrid approach that combines both approaches.
People who opt for a product-centric approach can be successful commercially, if they are able to get their pipelines up to the right stage, and then find a major pharmaceutical partner or a financier with deep pockets. This is a costly proposition but managing opportunistic approaches to leverage outside resources with the right scientific decision-making about projects that are homegrown is essential.
Alternately, the “platform” model offers an alternative way to earn revenue. It is less costly than product-oriented development, but has a significant risk. In this model biotechs own and develops its platform technology before working with large pharma companies to generate a portfolio of drug discovery projects that specifically target diseases (i.e., disease x in biology y). This is the approach that Advinus Therapeutics and a few others have taken.
